PitchSend

Investor Presentaiton

Investor Presentation First six months of 2018 Slide 11 In PIONEER 3 oral semaglutide showed superior reductions in HbA1c and weight vs sitagliptin after 78 weeks Reduction in HbA1c with oral semaglutide vs sitagliptin Reduction in body weight with oral semaglutide vs sitagliptin HbA1c reduction (%)¹ Weight loss (kg)¹ Oral sema Oral sema 3 mg 7 mg Oral sema 14 mg Sitagliptin 100 mg Oral sema 3 mg Oral sema 7 mg Oral sema 14 mg Sitagliptin 100 mg 0.0 0.0 -0.4 -0.3% -0.4% -1.0 -1.1 kg -0.8 -0.7 %* -1.2 -1.1%* -1.6 -2.0 -2.0 -1.9 kg* -3.0 -2.7 kg* -3.5 kg* -4.0 Results illustrated by using the secondary statistical method called hypothetical estimand after 78 weeks of treatment: Treatment effect, if all participants followed the treatment without rescue medication (analysed by using Mixed Models for Repeated Measurements (MMRM)). The statistical method is consistent with e.g. the statistical method used for the SUSTAIN programme for subcutaneous novo nordisk semaglutide. * Statistically significant versus sitagliptin Sema: semaglutide

View entire presentation